Blood Cancer Talks

In this episode, we take a deep dive into the management of newly diagnosed CLL with Dr. Nitin Jain from MD Anderson and discuss key clinical trials in the past decade that has shaped the current treatment paradigm.

Show Notes

Key articles and trials discussed in the episode:
1.      Excellent review in NEJM on treatment of CLL (2020):
2.     Alliance Trial (Ibrutinib vs chemoimmunotherapy in older patients with untreated CLL):
3.     E1912 (Ibrutinib vs chemoimmunotherapy in younger/fit patients with CLL):
4.     RCT testing Acalabrutinib vs Ibrutinib (non-inferiority) in relapsed CLL:
5.     ELEVATE-TN Study (Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab):
6.     CLL-11 trial (showed that obinutuzumab>rituximab in CLL):
7.      Initial data from German CLL-13 trial:
8.    Ventricular arrhythmia and sudden death with BTK inhibitor:\
9.    CLL14 trial (venetoclax-obinutuzumab in untreated CLL):
10.  Extended follow-up and MRD dynamics in CLL14 trial:
11.   CAPTIVATE Study on fixed-duration Ibrutinib-venetoclax in newly diagnosed CLL:
12.   Ibrutinib-Venetoclax for treatment of CLL:
13.   GLOW study (Ibrutinib-Venetoclax vs Chlorambucil-Obinutuzumab):

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk